IRIS International Inc. Stock Upgraded (IRIS)

NEW YORK ( TheStreet) -- IRIS International (Nasdaq: IRIS) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

Highlights from the ratings report include:
  • The revenue growth came in higher than the industry average of 8.6%. Since the same quarter one year prior, revenues rose by 13.1%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • IRIS has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 2.52, which clearly demonstrates the ability to cover short-term cash needs.
  • Looking at where the stock is today compared to one year ago, we find that it is not only higher, but it has also clearly outperformed the rise in the S&P 500 over the same period. Although other factors naturally played a role, the company's strong earnings growth was key. Looking ahead, unless broad bear market conditions prevail, we still see more upside potential for this stock, despite the fact that it has already risen over the past year.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 540.9% when compared to the same quarter one year prior, rising from $0.45 million to $2.90 million.
  • Net operating cash flow has significantly increased by 175.03% to $5.55 million when compared to the same quarter last year. In addition, IRIS INTERNATIONAL INC has also vastly surpassed the industry average cash flow growth rate of -5.41%.
.

IRIS International, Inc. manufactures in vitro diagnostic (IVD) products for urinalysis and body fluids. IRIS International has a market cap of $173 million and is part of the technology sector and electronics industry. Shares are up 18.7% year to date as of the close of trading on Friday.

You can view the full IRIS International Ratings Report or get investment ideas from our investment research center.
-- Written by a member of TheStreet RatingsStaff
null

If you liked this article you might like

IRIS International Inc. Stock Upgraded (IRIS)

IRIS International Inc. Stock Downgraded (IRIS)

IRIS International Inc. Stock Upgraded (IRIS)

IRIS International Inc. Stock Downgraded (IRIS)